Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Citations
50 citations
Cites background from "Targeted Therapies in Breast Cancer..."
...Genome sequencing technology advancements have led to a deeper understanding of cancer biology, and they have enabled identification of cancer-specific genomic alterations for potential targeted therapies [1, 3]....
[...]
32 citations
Cites background from "Targeted Therapies in Breast Cancer..."
...[70] Anit-HER2 mAbs and derivatives Approved monoclonal antibodies Trastuzumab (HERCEPTIN) Trastuzumab is a humanized monoclonal antibody which binds to domain IV of HER2....
[...]
...[7,33,104] It is more effective when HER3 activates HER2....
[...]
...It is worth noting that Pertuzumab and trastuzumab bind to different domains of HER2.([71,84,86]) Pertuzumab inhibits HER2 dimerization with other activated HER-family members such as HER3....
[...]
...[82,83] Pertuzumab (PERJETA) Pertuzumab is a humanized monoclonal antibody which binds to domain II of HER2....
[...]
...Szymanska M et al. A combination of two antibodies recognizing nonoverlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2....
[...]
25 citations
15 citations
Cites background from "Targeted Therapies in Breast Cancer..."
...As knowledge of the underlying molecular mechanisms responsible for tumor development and chemotherapeutic resistance has increased, contemporary treatment of breast cancer has entered an era of targeted therapies based on molecular typing, and examples of these molecular targeted therapeutics for breast cancer include tyrosine kinase inhibitors (TKIs), angiogenesis inhibitors and agents that perturb DNA repair (8)....
[...]
References
11,597 citations
"Targeted Therapies in Breast Cancer..." refers background in this paper
...ANTI-HER2/neu THERAPY Trastuzumab The HER2/neu oncogene, a transmembrane tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) family, has been shown to be amplified in up to 30% of human breast can- cer cell lines (Slamon et al., 1987)....
[...]
10,532 citations
"Targeted Therapies in Breast Cancer..." refers background in this paper
...…diarrhea, elevated liver enzymes, and palmar-plantar erythrodysesthesia (Agus et al., 2005; Baselga et al., 2010; Baselga & Swain, 2010; Gianni et al., 2010; Inoue et al., 2010; Marty et al., 2005; Pierga et al., 2010; Robert et al., 2006; Slamon et al., 2001; Wardley et al., 2010)....
[...]
...2% of patients treated with pertuzumab in combination with chemotherapy (Agus et al., 2005; Baselga et al., 2010; Baselga & Swain 2010; Gianni et al., 2010; Inoue et al., 2010; Marty et al., 2005; Pierga et al., 2010; Robert et al., 2006; Slamon et al., 2001; Wardley et al., 2010)....
[...]
...…and in 1.2% of patients treated with pertuzumab in combination with chemotherapy (Agus et al., 2005; Baselga et al., 2010; Baselga & Swain 2010; Gianni et al., 2010; Inoue et al., 2010; Marty et al., 2005; Pierga et al., 2010; Robert et al., 2006; Slamon et al., 2001; Wardley et al., 2010)....
[...]
...Other concerning grade 3 side effects of antiHER2/neu therapy include neutropenia, leukopenia, thrombocytopenia, diarrhea, elevated liver enzymes, and palmar-plantar erythrodysesthesia (Agus et al., 2005; Baselga et al., 2010; Baselga & Swain, 2010; Gianni et al., 2010; Inoue et al., 2010; Marty et al., 2005; Pierga et al., 2010; Robert et al., 2006; Slamon et al., 2001; Wardley et al., 2010)....
[...]
5,650 citations
"Targeted Therapies in Breast Cancer..." refers background in this paper
...PARP inhibitors have selective anticancer activity in BRCA1- and BRCA2-deficient cancers (Farmer et al., 2005; Bryant et al., 2005)....
[...]
5,200 citations
"Targeted Therapies in Breast Cancer..." refers background in this paper
...…with significantly longer overall survival (OS), longer time to tumor progression (TTP), and longer duration of response (Slamon et al., 2004; Romond et al., 2005; Piccart-Gebhart et al, 2005; Joensuu et al., 2006; Robert et al., 2006; Pierga et al., 2010; Marty et al., 2005; Inoue et al.,…...
[...]
...Pivotal phase II and III clinical trials of trastuzumab given in combination with chemotherapy to women with early-stage and metastatic breast cancer (MBC) have demonstrated that trastuzumab is associated with significantly longer overall survival (OS), longer time to tumor progression (TTP), and longer duration of response (Slamon et al., 2004; Romond et al., 2005; Piccart-Gebhart et al, 2005; Joensuu et al., 2006; Robert et al., 2006; Pierga et al., 2010; Marty et al., 2005; Inoue et al., 2010)....
[...]
4,815 citations